Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease
07.08.2025 - 18:05:30
Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader in complement structural biologyView original content:https://www.prnewswire.co.uk/news-releases/commit-biologics-launches-with-16m-seed-financing-to-pioneer-complement-system-activation-to-treat-cancer-and-autoimmune-disease-302140040.html
